#Netherlands #Utrecht #Prostate Cancer #Illuccix #PSMA-PET

Illuccix® PSMA-PET Imaging Agent Approved in the Netherlands

In a significant advancement for prostate cancer diagnostics, Telix Pharmaceuticals Limited has officially announced that its imaging agent, Illuccix® (gallium-68 gozetotide injection), has received marketing authorization from the Netherlands' Medicines Evaluation Board (MEB). This approval enables healthcare providers in the Netherlands to utilize a clinically validated radiopharmaceutical for detecting and localizing PSMA-positive lesions in adults diagnosed with prostate cancer.

A New Era in Prostate Cancer Imaging

The use of PSMA-PET imaging marks a pivotal shift in the management of prostate cancer, superseding traditional imaging techniques such as bone scans and CT scans. The approval of Illuccix® facilitates precise staging of the disease and enables timely identification of recurrent prostate cancer within clinical settings. It is particularly pivotal for patients considered at high risk prior to receiving primary curative therapies, those with rising PSA levels indicative of possible recurrence, and patients experiencing progression of metastatic castration-resistant prostate cancer (mCRPC).

Clinical guidelines worldwide recognize the superior accuracy of PSMA-PET in determining the stage of primary disease and evaluating biochemically recurrent prostate cancer (BCR). Illuccix® is essential in fulfilling an urgent need for effective diagnostics in this field, improving patient access to timely diagnosis and guiding therapy options focused on PSMA targeting.

Robust Clinical Support

The broad approval of Illuccix® is underpinned by extensive clinical data, including findings from the largest Ga-68 based PSMA dataset derived from the VISION study. The potential impact of PSMA-PET is echoed by Dr. Marnix Lam, a nuclear medicine professor at UMC Utrecht, who noted that PSMA-PET has significantly enhanced the accuracy and reliability of prostate cancer imaging compared to conventional methods. He stated, “The approval of Telix's PSMA-PET agent in the Netherlands means more hospitals can integrate this innovative technology into routine clinical practice, ultimately benefiting patients.”

Furthermore, Raphaël Ortiz, CEO of Telix International, expressed that this approval opens doors for a clinically validated PSMA-PET product, providing healthcare professionals with the convenience and flexibility of gallium produced by generators. This milestone represents Telix's commitment to enhancing prostate cancer care and expanding access to innovative diagnostic technologies across Europe.

Prostate Cancer Statistics in the Netherlands

Prostate cancer is the most prevalent cancer diagnosis among men in the Netherlands, with over 11,900 new cases reported annually. This number surpasses the incidences of colorectal cancer and lung cancer. Tragically, prostate cancer also ranks as the third leading cause of cancer-related deaths among men in the country, with more than 3,200 fatalities recorded in 2022 alone.

The marketing of Illuccix® not only positions Telix at the forefront of prostate cancer diagnostics but also significantly impacts the treatment landscape in helping medical professionals better identify and treat patients with this common yet serious condition.

For further inquiries about availability or to place orders for Illuccix®, healthcare professionals in the Netherlands can reach out via email to [email protected]

Conclusion

Telix Pharmaceuticals is forging ahead in the biopharmaceutical landscape, dedicated to addressing urgent medical needs in oncology, especially with respect to imaging and treatment options in prostate cancer. With the broad approval of Illuccix®, patients in the Netherlands and potentially wider European markets can expect enhanced diagnostic capabilities that can lead to better health outcomes.

For additional information about Telix and their latest developments, please visit their official website at Telix Pharmaceuticals.